Management of severe complications in Behçet’s disease with TNF inhibitors

References

• Saadoun D, Wechsler B, Desseaux K, et al. Mortality in Behçet’s disease. Arthritis Rheum. 2010;62(9):2806–2812.
   PubMed Web of Science ®Google Scholar
• Kural-Seyahi E, Fresko I, Seyahi N, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore). 2003;82(1):60–76.
   PubMed Web of Science ®Google Scholar
• Xavier JM, Shahram F, Davatchi F, et al. Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behçet’s disease. Arthritis Rheum. 2012;64(8):2761–2772.
   PubMed Web of Science ®Google Scholar
• Pineton de Chambrun M, Wechsler B, Geri G, et al. New insights into the pathogenesis of Behçet’s disease. Autoimmun Rev. 2012;11(10):687–698.
   PubMed Web of Science ®Google Scholar
• Geri G, Terrier B, Rosenzwajg M, et al. Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet disease. J Allergy Clin Immunol. 2011;128(3):655–664.
   PubMed Web of Science ®Google Scholar
• Saadoun D, Asli B, Wechsler B, et al. Long-term outcome of arterial lesions in Behçet disease: a series of 101 patients. Medicine (Baltimore). 2012;91(1):18–24.
   PubMed Web of Science ®Google Scholar
• Akman A, Sallakci, N, Coskun M, et al. TNF-a gene 1031 T/C polymorphism in Turkish patients with Behc¸et’s disease. Br J Dermatol. 2006;155:350–356.
   PubMed Web of Science ®Google Scholar
• Calvo-Rio V, Blanco R, Beltran E, et al. Anti-TNF- therapy in patients with refractory uveitis due to Behcet’s disease: a 1-year follow-up study of 124 patients. Rheumatology. 2014;53(12):2223–2231.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478–2484.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.
   PubMed Web of Science ®Google Scholar
• Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behçet’s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61–70.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Kaklamanis PH, Elezoglou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med. 2004;140:404–406.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the french uveitis network: anti-tnf in noninfectious inflammatory uveitis. Arthritis Rheumatol. 2016;68(6):1522–1530.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943.
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183–1192.
   PubMed Web of Science ®Google Scholar
• Hamza MM, Macky TA, Sidky MK, et al. Intravitreal infliximab in refractory uveitis in behcet’s disease: a safety and efficacy clinical study. Retina. 2016;36:2399–2408.
   PubMed Web of Science ®Google Scholar
• Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32:S58–S62.
   PubMed Web of Science ®Google Scholar
• Fabiani C, Vitale A, Emmi G, et al. Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183–189.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis. 2008;67(12):1656–1662.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–796.e3.
   PubMed Web of Science ®Google Scholar
• Le Thi Huong DU, Vidailhet MJ, Wechsler B, et al. [Value of the cyclophosphamide bolus in severe systemic diseases. Preliminary results]. Presse Médicale Paris Fr 1983. 1988;17(11):524–527. French.
   Google Scholar
• Hamuryudan V, Er T, Seyahi E, et al. Pulmonary artery aneurysms in Behçet syndrome. Am J Med. 2004;117(11):867–870.
   PubMed Web of Science ®Google Scholar
• Seyahi E, Melikoglu M, Akman C, et al. Pulmonary artery involvement and associated lung disease in Behçet disease: a series of 47 patients. Medicine (Baltimore). 2012;91(1):35–48.
   PubMed Web of Science ®Google Scholar
• Seyahi E, Caglar E, Ugurlu S, et al. An outcome survey of 43 patients with Budd–Chiari syndrome due to Behçet’s syndrome followed up at a single, dedicated center. Semin Arthritis Rheum. 2015;44(5):602–609.
   PubMed Web of Science ®Google Scholar
• Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016;95(24):e3863.
   PubMed Web of Science ®Google Scholar
• Desbois AC, Biard L, Addimanda O, et al. Efficacy of anti-TNF alpha in severe and refractory major vessel involvement of Behcet’s disease: a multicenter observational study of 18 patients. Autoimmun Rev. Forthcoming.
   Google Scholar
• Chan E, Sangle SR, Coghlan JG, et al. Pulmonary artery aneurysms in Behçet’s disease treated with anti-TNFα: a case series and review of the literature. Autoimmun Rev. 2016;15:375–378.
   PubMed Web of Science ®Google Scholar
• Baki K, Villiger PM, Jenni D, et al. Behcet’s disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment. Ann Rheum Dis. 2006;65(11):1531–1532.
   PubMed Web of Science ®Google Scholar
• Hamuryudan V, Seyahi E, Ugurlu S, et al. Pulmonary artery involvement in Behçet׳s syndrome: effects of anti-Tnf treatment. Semin Arthritis Rheum. 2015;45(3):369–373.
   PubMed Web of Science ®Google Scholar
• Seyahi E, Hamuryudan V, Hatemi G, et al. Infliximab in the treatment of hepatic vein thrombosis (Budd-Chiari syndrome) in three patients with Behcet’s syndrome. Rheumatol Oxf Engl. 2007;46(7):1213–1214.
   PubMed Web of Science ®Google Scholar
• Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study. J Rheumatol. 2005 Jan;32(1):98–105.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Leccese P, D’Angelo S, et al. Efficacy of adalimumab in patients with Behçet’s disease unsuccessfully treated with infliximab. Clin Exp Rheumatol. 2011;29.
   Web of Science ®Google Scholar
• Noel N, Bernard R, Wechsler B, et al. Long-term outcome of neuro-Behçet’s disease: outcome of neuro-Behçet’s disease. Arthritis Rheumatol. 2014;66(5):1306–1314.
   PubMed Web of Science ®Google Scholar
• Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum. 2008;59(2):285–290.
   PubMed Web of Science ®Google Scholar
• Zeydan B, Uygunoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Behçet disease. Neurol Neuroimmunol Neuroinflamm. 2016;3:e258.
   PubMed Web of Science ®Google Scholar
• Desbois AC, Addimanda O, Bertrand A, et al. Efficacy of anti-tnfα in severe and refractory neuro-Behcet disease: an observational study. Medicine (Baltimore). 2016;95(23):e3550.
   PubMed Web of Science ®Google Scholar
• Kinoshita H, Kunisaki R, Yamamoto H, et al. Efficacy of infliximab in patients with intestinal Behçet’s disease refractory to conventional medication. Intern Med. 2013;52(17):1855–1862.
   PubMed Web of Science ®Google Scholar
• Iwata S, Saito K, Yamaoka K, et al. Effects of anti-TNF- antibody infliximab in refractory entero-Behcet’s disease. Rheumatology. 2009;48(8):1012–1013.
   PubMed Web of Science ®Google Scholar
• Iwata S, Saito K, Yamaoka K, et al. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet’s disease. Mod Rheumatol. 2011;21(2):184–191.
   PubMed Web of Science ®Google Scholar
• Lee JH, Cheon JH, Jeon SW, et al. Efficacy of infliximab in intestinal Behçet’s disease: a Korean multicenter retrospective study. Inflamm Bowel Dis. 2013;19:1833–1838.
   PubMed Web of Science ®Google Scholar
• Zou J, Ji D-N, Cai J, et al. Predictors of sustained response in patients with intestinal Behcet’s disease treated with infliximab. Dig Dis Sci. 2017;62(2):441–447.
   PubMed Web of Science ®Google Scholar
• Tanida S, Inoue N, Kobayashi K, et al. Adalimumab for the treatment of Japanese patients with intestinal Behçet’s disease. Clin Gastroenterol Hepatol. 2015;13(5):940–948.e3.
   PubMed Web of Science ®Google Scholar
• Tanida S, Mizoshita T, Nishie H, et al. Long-term efficacy of adalimumab in patients with intestinal Behcet’s disease: eight consecutive cases. J Clin Med Res. 2016;8(4):334–337.
   PubMedGoogle Scholar
• Hatemi I, Hatemi G, Pamuk ON, et al. TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet’s syndrome refractory to the conventional treatment modalities: a case series and review of the literature. Clin Exp Rheumatol. 2015;33:S129–S137.
   PubMed Web of Science ®Google Scholar
• Hisamatsu T, Ueno F, Matsumoto T, et al. The 2nd edition of consensus statements for the diagnosis and management of intestinal Behçet’s disease: indication of anti-TNFα monoclonal antibodies. J Gastroenterol. 2014;49(1):156–162.
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis. 2011;70(4):616–623.
   PubMed Web of Science ®Google Scholar
• Moulis G, Sommet A, Béné J, et al. Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. Plos ONE. 2012;7(11):e48991.
   PubMed Web of Science ®Google Scholar
• Borekci S, Atahan E, Demir Yilmaz D, et al. Factors affecting the tuberculosis risk in patients receiving anti-tumor necrosis factor-α treatment. Respiration. 2015;90:191–198.
   PubMed Web of Science ®Google Scholar
• Capella MJ, Foster CS. Long-term efficacy and safety of infliximab in the treatment of Behçet’s disease. Ocul Immunol Inflamm. 2012;20(3):198–202.
   PubMed Web of Science ®Google Scholar
• Kalra S, Silman A, Akman-Demir G, et al. Diagnosis and management of Neuro-Behçet’s disease: international consensus recommendations. J Neurol. 2014;261(9):1662–1676.
   PubMed Web of Science ®Google Scholar
• Handa T, Tsunekawa H, Yoneda M, et al. Long-term remission of ocular and extraocular manifestations in Behçet’s disease using infliximab. Clin Exp Rheumatol. 2011;29:S58–S63.
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behçet’s syndrome — a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–1518.
   PubMed Web of Science ®Google Scholar
• Vitale A, Rigante D, Caso F, et al. Inhibition of interleukin-1 by canakinumab as a successful mono-drug strategy for the treatment of refractory Behçet’s disease: a case series. Dermatology. 2014;228:211–214.
   PubMed Web of Science ®Google Scholar
• Caso F, Costa L, Rigante D, et al. Biological treatments in Behçet’s disease: beyond anti-TNF therapy. Mediators Inflamm. 2014;2014:1–14.
   Web of Science ®Google Scholar
• Addimanda O, Pipitone N, Pazzola G, et al. Tocilizumab for severe refractory neuro-Behçet: three cases IL-6 blockade in neuro-Behçet. Semin Arthritis Rheum. 2015;44(4):472–475.
   PubMed Web of Science ®Google Scholar